Open AccessIn Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2,440 Clinical Isolates
Author(s) -
Heather J. Adam,
Nancy M. Laing,
Chi-Hsin R. King,
Ben Lulashnyk,
Daryl J. Hoban,
George G. Zhanel
Publication year - 2009
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00078-09
Subject(s) - microbiology and biotechnology , moxifloxacin , enterococcus faecalis , staphylococcus epidermidis , acinetobacter baumannii , levofloxacin , streptococcus pneumoniae , klebsiella pneumoniae , ofloxacin , klebsiella oxytoca , staphylococcus aureus , pseudomonas aeruginosa , biology , antibiotics , ciprofloxacin , bacteria , escherichia coli , biochemistry , genetics , gene
The in vitro activity of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, was tested against 2,440 clinical isolates. Nemonoxacin was at least fourfold more active than levofloxacin and moxifloxacin against most gram-positive cocci tested (shown by the following MIC90 /range [μg/ml] values; community-associated methicillin [meticillin]-resistantStaphylococcus aureus , 0.5/0.015 to 2;Staphylococcus epidermidis , 0.5/0.015 to 4 for methicillin-susceptible staphylococci and 2/0.12 to 2 for methicillin-resistant staphylococci;Streptococcus pneumoniae , 0.015/≤0.008 to 0.25;Enterococcus faecalis , 1/0.03 to 128). Nemonoxacin activity against gram-negative bacilli was similar to levofloxacin and moxifloxacin (MIC90 /range [μg/ml];Escherichia coli , 32/≤0.015 to ≥512;Klebsiella pneumoniae , 2/≤0.015 to 128;K .oxytoca , 0.5/0.06 to 1;Proteus mirabilis , 16/0.25 to ≥512;Pseudomonas aeruginosa , 32/≤0.015 to ≥512;Acinetobacter baumannii , 1/0.12 to 16).